Drug Trial Radar · NCT01594749
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)
Last checked: Nov 19, 2026Latest source record: Sep 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,015
Actual
Start
Sep 24, 2012
Primary completion
Nov 3, 2014
Study completion Nov 3, 2014
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 9, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to demonstrate that, when given concomitantly with a 5-hydroxytryptamine 3 (5-HT3) antagonist and a corticosteroid, a single 150 mg intravenous (IV) dose of fosaprepitant given on Day 1 is superior to the control regimen of 5-HT3 antagonist and corticosteroid only, in preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC).
Conditions
- Chemotherapy-Induced Nausea and Vomiting (CINV)
Interventions
Fosaprepitant dimeglumineDrug
Fosaprepitant PlaceboDrug
DexamethasoneDrug
OndansetronDrug
Dexamethasone PlaceboDrug
Ondansetron PlaceboDrug
Rescue TherapyDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Complete Response From 25 to 120 Hours After Initiation of Moderately Emetogenic Chemotherapy (MEC)Time frame: 25 to 120 hours after initiation of MEC
- Percentage of Participants With Infusion-site ThrombophlebitisTime frame: Day 1 through Day 17, inclusive
- Percentage of Participants With Severe Infusion-site ReactionsTime frame: Day 1 through Day 17, inclusive
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.